Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Conditions
Keywords
women
Brief summary
Among postmenopausal women who suffer from recurrent urinary tract infections (UTI), vaginal estrogen therapy prevents UTI recurrences for 50% of sufferers. This research will investigate why some women benefit but others do not, focusing on (a) the effects of vaginal estrogen therapy on the bacteria that inhabit the vagina and bladder, (b) its influence on immune responses in both compartments, and (c) the extent to which those changes are critical to successful UTI prevention. The findings will be a first step in the development of more effective strategies to prevent UTI, one of the most common and costly benign urologic conditions.
Detailed description
Recurrent urinary tract infections (rUTI) are a significant problem among older women: 13% of female Medicare beneficiaries experience at least one UTI annually and \>40% of these develop chronic recurrent UTI. Although UTIs are significantly reduced by vaginal estrogen therapy (VET), 50% of those using VET continue to experience UTI recurrences. It is unknown why some women benefit from VET while others do not. This application focuses on interrogating two mechanisms likely to be central to the effectiveness of VET. The first is the urogenital microbiota: an increase in vaginal lactobacilli is the purported mechanism by which VET reduces rUTI. Important and unanswered questions include how VET influences specific Lactobacillus spp., whether changes to specific Lactobacillus spp are the key to successful prophylaxis, and how VET affects the urinary microbiota. A second mechanism addressed by this application is the host vaginal and urinary immune response. Estrogen appears to influence localized urogenital immune responses, including Th17 and Th1 versus Th2 pathway signaling. Animal studies suggest that these compartmentalized immune responses play a critical role in UTI susceptibility, but human data are lacking. This application will address these unanswered questions. Postmenopausal women with rUTI will be treated with VET. Samples collected before and after VET will characterize vaginal and urinary microbiota, soluble mediators of inflammation in both compartments, and vaginal D-lactic acid. Aims 1 and 2 of this proposal will investigate the impact of VET on the urogenital microbiota and urogenital immune responses, respectively. Aim 3 will characterize the urogenital environments of participants who continue to experience rUTI during VET versus those who remain UTI-free. The accomplishment of these aims will provide pilot data for a larger and more definitive clinical trial. These proposed studies are a key step toward the investigators' goals of identifying biomarkers that reliably predict a successful response to rUTI prophylaxis and ascertaining the biological conditions required for successful UTI prevention. Ultimately, an understanding of the mechanisms of rUTI prevention will allow the development of novel and effective prevention strategies for postmenopausal women suffering from rUTI.
Interventions
Vaginal estradiol tablets (10mcg).
Sponsors
Johns Hopkins University
University of Maryland
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Open label, single group clinical trial
Eligibility
Sex/Gender
FEMALE
Age
55 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Participants in this study will be * Postmenopausal women (menopausal for at least 1 year) * Minimum age of 55 years * Participants will have documentation of recurrent UTI, defined as follows: * History of treatment for at least 3 UTIs in the past year or 2 episodes within 6 months AND * At least one positive urine culture during an acute symptomatic episode.
Exclusion criteria
* Women receiving antibiotic prophylaxis to prevent UTI recurrence; * Women with contraindications to vaginal estrogen (as indicated on the FDA-mandated package insert) and those who have used vaginal or systemic estrogen within the past 6 months; * Women with an active UTI and those who have received antibiotics within the prior 2 weeks; * Women with complicated rUTI, defined by immune compromise, anatomic or functional abnormalities of the urinary tract, indwelling catheterization, those performing self-catheterization, and those with neurological disease or illness relevant to the lower urinary tract; * Women with only asymptomatic bacteriuria (rather than recurrent symptomatic UTI)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Vaginal Microbiota | Baseline and 12 weeks | Changes to relative vaginal abundance of key Lactobacillus spp. before and after treatment. |
| Change in Vaginal Interleukin-6 Level | Baseline and 12 weeks | Changes to vaginal Interleukin-6 before and after treatment. |
| Change in Urinary Microbiota | Baseline and 12 weeks | Changes to relative urinary abundance of key Lactobacillus spp. before and after treatment. |
| Change in Urinary Interleukin-6 Level | Baseline and 12 weeks | Changes to urinary Interleukin-6 before and after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Tract Infection Recurrence | Weeks 12 to 24 | Participants with at least one occurrence of symptomatic UTI after at least 12 weeks of therapy. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORVictoria Handa, MD MHS
Johns Hopkins University
Participant flow
Pre-assignment details
Twenty-seven participants signed informed consent. Two participants never started the study. Twenty-five participants were assigned to the treatment arm of the study.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 68 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 23 Participants |
| Region of Enrollment United States | 25 Participants |
| Sex: Female, Male Female | 25 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 25 |
| other Total, other adverse events | 1 / 25 |
| serious Total, serious adverse events | 0 / 25 |
Outcome results
None listed